Vacc-4x: Additional Phase I/II data

Data from 17 evaluable patients with HIV-1 infection in Part B of the open-label, Danish Phase I/II REDUC trial showed that Vacc-4x plus GM-CSF adjuvant followed by 5

Read the full 280 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE